Evaluation of 3-Month Data for the Use of Erenumab for Chronic Migraine in Glasgow

    Krishna Dani, Lesley Murray, Anissa Benchiheub … Alok Tyagi
    Studysummary In this study, 81% of patients with chronic migraine in Glasgow continued using erenumab for significant headache reduction at three months, suggesting a high response rate.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →